<DOC>
	<DOCNO>NCT02129985</DOCNO>
	<brief_summary>Whether GLP-1 receptor agonists sequential therapy newly diagnose type 2 diabetic patient improve glycemic control , diabetes remission rate β-cell function short-term insulin intensive therapy .</brief_summary>
	<brief_title>Effect Beta Cell Function Glycaemic Control After Insulin Exenatide Sequential Therapy</brief_title>
	<detailed_description>The UK Prospective Diabetes Study show β-cell function progressively deteriorate time people type 2 diabetes mellitus , irrespective lifestyle exist pharmacological intervention . The progressive nature type 2 diabetes one major challenge treatment affect patient , agent could alter natural history condition would add greatly current treatment approaches.Short-term intensive insulin therapy newly diagnose type 2 diabetes prove improve beta-cell function usually lead temporary remission time , remission rate year 50 % . The effect GLP-1 receptor agonists beta-cells stimulation glucose-dependent insulin release , follow enhancement insulin biosynthesis . It stimulate beta-cell proliferation , induction islet neogenesis , inhibition ß-cell apoptosis . Exenatide GLP-1 receptor agonist . Exenatide exert direct effect β-cell , indicate may contribute delay disease progression . However , study evaluate effect short-term intensive insulin sequential exenatide therapy model β-cell function glycemic remission rate newly diagnose type 2 diabetic patient . Our hypothesis whether GLP-1 receptor agonists sequential therapy newly diagnose type 2 diabetic patient improve glycemic control , diabetes remission rate β-cell function short-term insulin intensive therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>newly diagnose type 2 diabetes without drug treatment 2570 year old age Fasting glucose 7.016.7mmol / L BMI 20 ~ 35 kg/m2 stable least 3 month ( weight fluctuation within three month exceed 10 % ) females plan pregnancy study acute chronic complication diabetes myocardial infarction cerebrovascular event within three month serious gastrointestinal disease serious concomitant disease liver kidney dysfunction : Transaminase ( ALT AST ) great 3 time upper limit normal range creatinine level great 133μmol / L GAD antibody positive history pancreatitis pancreatic cancer ; pregnant breastfeeding woman . severe hypertension ( blood pressure &gt; 180/110mmhg ) use corticosteroid , immunosuppressant cytotoxic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>newly onset type 2 diabetes</keyword>
	<keyword>short-term insulin treatment</keyword>
	<keyword>exenatide sequential therapy</keyword>
	<keyword>beta cell function</keyword>
	<keyword>glycaemic remission</keyword>
</DOC>